logo
Plus   Neg
Share
Email

AstraZeneca, Eli Lilly To Discontinue Lanabecestat Trials In Alzheimer's

AstraZeneca (AZN.L,AZN) and Eli Lilly and Company announced they are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibitor, for the treatment of Alzheimer's disease. The decision is based on recommendations by an independent data monitoring committee. The committee concluded that both the AMARANTH trial, in early Alzheimer's disease, and the DAYBREAK-ALZ trial, in mild Alzheimer's disease dementia, were not likely to meet their primary endpoints upon completion.

The AstraZeneca and Lilly BACE alliance for lanabecestat remains in place and the companies will now work with the clinical trial sites involved to implement the discontinuations.

AstraZeneca said the discontinuation of the lanabecestat Phase III clinical trials in Alzheimer's disease is not expected to have a material impact on the company's financial guidance for 2018, which therefore remains unchanged.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Chinese e-commerce giant Alibaba Group Holding Limited and rival JD.com have set new sales records for the "Singles Day" online shopping event. Alibaba said Sunday that it generated gross merchandise volume or GMV of 213.5 billion yuan, or $30.8 billion on November 11, 2018, representing an increase of 27 percent compared to 2017. The Singles Day shopping festival began in 2009. Japanese conglomerate SoftBank Group Corp. said Monday it has received approval from the Tokyo Stock Exchange for listing of common stock of its Japanese mobile telecoms unit, SoftBank Corp. SoftBank plans to sell shares worth 2.4 trillion yen, or $21 billion, in its domestic mobile telecom unit. This would make it the world's biggest IPO after Alibaba's $25 billion IPO in 2014. Shares of Infineon Technologies AG were losing around 4 percent in the morning trading in Germany after the semiconductor solutions company reported Monday weak net profit in its fourth quarter. Income from continuing operations, however, grew with strong revenue growth. The company also increased its full-year dividend.
Follow RTT